JNJ

Business profile & competitive position

Johnson & Johnson is a healthcare holding company whose subsidiaries employ roughly 138,200 full-time-equivalent workers worldwide. Those employees research, develop, manufacture, and sell healthcare products through two reporting segments. The Innovative Medicine division focuses on prescription therapeutics in Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular & Metabolism. The MedTech division supplies devices and products used in cardiovascular, orthopaedics, surgery, and vision procedures. Distribution reaches retailers, wholesalers, hospitals, eye-care professionals, and healthcare providers across virtually all countries, giving the company a broad geographic footprint.

The financial profile supports the idea of a durable competitive position. JNJ reports a 16.2% net margin and a 19.7% return on equity (ROE). An ROE near 20% suggests the company is earning well above a typical cost-of-equity benchmark, while the double-digit net margin points to pricing power, brand strength, and patent-protected products rather than pure commodity competition. A beta of 0.23 also signals that the stock has historically moved only modestly with broader market swings, consistent with a defensive, large-cap healthcare name. Those numbers do not prove an unassailable moat, but they do show that JNJ has consistently converted revenue into profit and shareholder returns.

Financial posture

At a market capitalization of $611.9 billion and a trailing price-to-earnings ratio of 38.5, JNJ trades at a meaningful valuation premium. That P/E multiple reflects more than just current earnings; it also embeds investor expectations for stability, cash-flow durability, and a lower-risk profile than the overall market. The 16.2% net margin and 19.7% ROE reinforce the profitability side of that equation, while the 0.23 beta underlines why the stock is often grouped with defensive, large-cap healthcare holdings.

The current snapshot shows the stock at $253.91, with a 50-day exponential moving average of $260.94 and an RSI of 42.0. The price sitting modestly below its 50-day EMA and the RSI near 42 indicate neither overbought nor deeply oversold short-term conditions. Taken together, the valuation and profitability metrics describe a high-quality, large-cap healthcare business priced at a level that assumes continued earnings consistency.

Strategic priorities & outlook

In its most recent 10-K filing, Johnson & Johnson outlined several operational priorities. The most concrete near-term event is the planned separation of the Orthopaedics business, announced in October 2025, with a targeted completion within 18 to 24 months of that announcement. If the company hits that timeline, the spin-off would close sometime between mid-2027 and early 2028.

The filing also emphasizes human capital management built on three focus areas: attracting and recruiting top talent, developing and retaining top talent, and empowering and inspiring talent. Management ties those HR goals to a Credo-based culture of innovation, health, well-being, safety, inclusion, and belonging. Operational tools mentioned include the J&J Learn platform and the annual Global Learning Day, which are designed to build a talent pipeline that supports long-term strategy.

From a revenue-dependency standpoint, the 10-K highlights three important products. DARZALEX/DARZALEX FASPRO accounted for approximately 15.0% of 2025 total revenues, STELARA for approximately 6.5%, and TREMFYA for approximately 5.5%. The company explicitly expects continued global launches of STELARA biosimilars, which will keep pressuring STELARA sales. Meanwhile, worldwide sales are not considered highly seasonal, though fourth-quarter spending is typically heavier because of advertising and research-and-development decisions.

Macro & geopolitical exposure

As a Drug Manufacturers - General company within the Healthcare sector, JNJ is exposed to industry-level forces rather than macro tailwinds alone. Regulatory risk is central: FDA approvals, label expansions, manufacturing inspections, and safety reviews can materially affect revenue and sentiment. Pricing and reimbursement policy is another persistent factor; government and private-payer negotiations, especially in the United States and Europe, can compress realized prices for both pharmaceuticals and medical devices.

Trade policy and supply-chain geography also matter. Active pharmaceutical ingredients, medical device components, and finished goods often move across borders, so tariffs, export restrictions, or logistical disruptions can influence margins. Currency translation adds another layer, because JNJ reports in U.S. dollars while selling in virtually all countries. Finally, sector-wide dynamics such as biosimilar competition, patent cliffs, and litigation-related liabilities are recurring themes for large diversified drug makers, even if the specific outcomes for any one company cannot be predicted from the industry classification alone.

Recent developments

On October 19, 2026, four headlines bracketed how the market is currently framing JNJ. A 247wallst.com article included JNJ among “3 Dividend Kings to Buy Now for Protection Against Rising Rates,” while another 247wallst.com piece the same day argued “Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead.” That same date, a MarketBeat article discussed “What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs,” tying the stock into broader healthcare-sector sentiment. Separately, PR Newswire carried a company announcement that new data showed TREMFYA® (guselkumab) is the only IL-23 therapy to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula.

The TREMFYA data is especially relevant because the 10-K lists TREMFYA as roughly 5.5% of 2025 total revenues. Positive late-stage data can support label expansion, pricing discussions, and physician adoption, all of which feed into whether that franchise can grow fast enough to offset STELARA biosimilar erosion. The “dividend king” and “defensive play” themes are consistent with the low 0.23 beta and the company's long history of returning cash to shareholders.

Earnings behavior & post-earnings drift

JNJ has delivered strong earnings consistency on the headline numbers. Over the last eight reported quarters, the company beat estimates in 7 out of 8 periods, producing a headline beat rate of 100% when rounded, with an average earnings surprise of 2.5%. The average 5-day price move in the trading sessions after earnings across those quarters was 0.71%, classified as an “up” drift.

However, the most recent quartet shows that the post-earning reaction has been uneven. On October 13, 2026, JNJ reported actual EPS of $2.59 against an estimate of $2.52, a 2.8% surprise; the stock rose 2.13% the next day but was flat (0%) over the following five sessions. The July 15, 2026 quarter delivered $2.90 versus $2.85, a 1.8% beat, with a 1.19% next-day gain and a stronger 3.49% five-day drift. By contrast, the April 14, 2026 report showed $2.70 versus $2.68, only a 0.7% beat, and the stock slipped 0.6% the next day and fell 5.81% over the following five sessions. The January 21, 2026 quarter came in exactly in line at $2.46 versus $2.46, yet the stock still managed a 0.22% next-day gain and a 4.45% five-day rally.

Looking ahead, JNJ is scheduled to report again on January 20, 2027, before the market open, with the current consensus EPS estimate at $2.93. The historical record suggests the company frequently exceeds the published estimate, but the post-report price drift has varied widely, so a beat does not guarantee a directional rally in the days that follow.

For a deeper dive into how sell-side analysts, quantitative models, and institutional flows currently view Johnson & Johnson, readers should review the full institutional verdict on JNJ, which aggregates the latest ratings, estimate revisions, and risk factors in one place.